EGFR and lung adenocarcinoma: In contrast to EGFR mutant lung adenocarcinomas, in which the T790M gatekeeper mutation is commonly selected following EGFR inhibitor exposure [72], there was no evidence of selection for mutations in specific genes in the post-treatment IBC tumours.